查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1922902

丙型肝炎抗病毒药物市场依产品类型、作用机制、治疗类型、剂型、基因型、通路和最终用户划分－2026-2032年全球预测

Antiviral Drugs for the Treatment of Hepatitis C Market by Product Type, Mechanism Of Action, Therapy Type, Formulation, Genotype, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，C型肝炎抗病毒药物市场价值将达到 156.7 亿美元，到 2026 年将成长至 168.7 亿美元，到 2032 年将达到 278.9 亿美元，复合年增长率为 8.57%。

关键市场统计数据
基准年 2025 156.7亿美元
预计年份：2026年 168.7亿美元
预测年份 2032 278.9亿美元
复合年增长率 (%) 8.57%

针对不断变化的丙型肝炎抗病毒治疗格局，提供全面指导，并为决策者明确临床、商业性和营运方面的优先事项。

丙型肝炎仍然是全球公共卫生领域的重点问题，其治疗格局在过去十年中发生了快速变化。抗病毒科学的进步重新定义了临床预期，使治疗方案从副作用较多的长期疗程转变为针对特定病毒蛋白的短期高效抗病毒疗法。这些治疗进展从根本上改变了医疗服务提供者的行为、支付方的评估框架以及患者的期望，并持续影响着重点投资和创新领域。

快速的治疗创新、价格压力和不断变化的经销管道如何重塑临床路径、商业模式和生产选择

治疗创新彻底改变了丙型肝炎的整个治疗流程，促进了新的商业模式和临床路径的出现。强效直接抗病毒药物（DAA）的出现，使治疗目标从病毒抑制转变为持续病毒学反应（SVR），即接近治癒。这改变了转诊模式、检测奖励以及慢性病管理的经济模式。因此，相关人员正在重新调整资源配置，致力于早期诊断、简化治疗流程以及采用泛基因型治疗方法，从而减少对基因型特异性决策树的需求。

评估关税对2025年丙型肝炎药物供应链韧性、采购行为、定价策略和病患获取趋势的影响

2025年关税环境对C型肝炎抗病毒药物领域的供应链、筹资策略和病患用药途径产生了多方面的影响。原料药和製剂进口成本的上升迫使生产商和经销商重新评估其全球筹资策略，加快对替代供应商的资格认证，并更多地依赖区域契约製造来降低成本波动。虽然这些措施在许多情况下维持了供应的连续性，但也前置作业时间，并增加了品质监管的复杂性。

以洞察为驱动的细分框架，将产品类型、作用机制、治疗模式、通路、最终用户、剂型和基因型与策略性商业性和临床决策联繫起来。

各细分市场的具体趋势将决定丙型肝炎治疗市场的临床应用模式、商业性定位和营运重点。直接抗病毒药物 (DAA)、干扰素和Ribavirin之间的差异持续影响处方行为和治疗优化，其中 DAA 是现代治疗方法的基础，而干扰素和Ribavirin则在特定临床环境中发挥重要作用。基于作用机制的细分有助于明确临床价值提案：NS3/4A 蛋白酶抑制剂可快速抑制病毒，而 NS5A 抑制剂则能有效抑制复製复合物。此外，NS5B聚合酵素抑制剂分为核苷类和非核苷类，它们既具有增强的遗传屏障特性，又能与其他药物互补，从而有利于联合治疗的设计。

区域性指令和差异化准入策略旨在适应全球市场中不同的监管、采购和医疗服务提供。

区域趋势将对丙型肝炎治疗药物的监管策略、取得途径和商业性应用产生决定性影响。在美洲，支付方和公共卫生计画优先考虑大规模筛检工作和高效获取泛基因型治疗方案，鼓励生产商将产品上市与国家消除目标相衔接，并在可能的情况下协商按疗效付费协议。同时，私营和公共部门的定价谈判要求企业证明其治癒导向型治疗方案的实际价值和成本优势。

药物研发公司、非专利公司和生产合作伙伴之间的竞争动态和策略联盟正在重新定义治疗方法差异化和市场进入策略。

领先的製药和生物技术公司的企业策略和竞争定位正在影响丙型肝炎治疗的近期商业性成果和长期发展。现有创新药物企业透过拓展适应症、覆盖全基因型以及开展真实世界证据计画来维持其高端市场地位，同时透过新製剂和简化给药方案来推进生命週期管理。同时，新参与企业和非专利生产商正在加剧价格敏感型细分市场的竞争，他们往往专注于批量竞标和开拓新兴市场。

为开发商和支付方提供可操作、高影响力的企业策略和临床步骤，以确保永续取得、降低供应风险并加速以患者为中心的丙型肝炎治疗。

产业领导者应优先采取一系列切实可行的措施，将洞察转化为市场优势。首先，投资泛基因型联合治疗以及能够证明缩短疗程可提高疗效和安全性的证据至关重要。这些数据将减轻临床医生和支付方的负担，并扩大其服务的患者群体。其次，建立灵活的生产网络和策略供应商关係将有助于降低关税和前置作业时间风险。区域契约製造和关键中间体的双重采购尤其有效。

采用稳健的混合调查方法，结合相关人员访谈、监管和临床证据综合以及情境分析，以检验策略洞见。

本执行摘要的研究采用了混合方法，兼顾与关键相关人员的直接对话和系统的二手证据综合分析。主要研究包括对临床医生、支付方、采购专业人员以及製药公司和契约製造组织的高阶主管进行结构化访谈，从而获得关于处方行为、竞标趋势和供应链限制的真实观点。二手研究包括对同侪审查文献、监管申报文件、临床试验註册资讯和公共卫生计画文件进行全面审查，以验证临床疗效、安全性以及政策趋势。

策略整合将治疗方法进展、进入限制和业务永续营运连续性相结合，凸显了推进治疗方法和维持市场永续性的重要性。

总而言之，C型肝炎治疗领域呈现出快速的科学进步、不断变化的商业模式以及日益严峻的准入挑战，这些因素共同为生产商、支付方和医疗保健系统带来了紧迫性和机会。儘管治疗方法的进步简化了临床决策并扩大了治癒的可能性，但价格压力、关税带来的供应风险以及各地不同的需求都要求企业采取灵活的策略。那些能够将临床开发与可行的准入途径相结合、实现生产和分销管道多元化并投资于真实世界证据的机构，将更有利于实现商业性成功和公共卫生影响的双重目标。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 丙型肝炎抗病毒药物市场（依产品类型划分）

  • 直接作用抗病毒药物
  • 干扰素
  • Ribavirin

9. 丙型肝炎抗病毒药物市场依作用机转划分

  • NS3/4A蛋白酶抑制剂
  • NS5A抑制剂
  • NS5B聚合酵素抑制剂
    • 非核苷类抑制剂
    • 核苷类抑制剂

10. 丙型肝炎抗病毒药物市场（依治疗方法）

  • 联合治疗
  • 单药治疗

第十一章 丙型肝炎治疗抗病毒药物市场（依剂型划分）

  • 注射
  • 口服

第十二章 丙型肝炎抗病毒药物市场（依基因型划分）

  • 基因型 1
  • 基因型 2
  • 基因型 3
  • 基因型 4
  • 基因型 5
  • 基因型 6

第十三章 丙型肝炎抗病毒药物市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 丙型肝炎抗病毒药物市场（依最终用户划分）

  • 诊所
  • 居家医疗
  • 医院

第十五章 各地区C型肝炎抗病毒药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 丙型肝炎抗病毒药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国丙型肝炎抗病毒药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国C型肝炎治疗抗病毒药物市场

第十九章 中国C型肝炎治疗抗病毒药物市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Cadila
Product Code: MRR-867BED9A9E44

The Antiviral Drugs for the Treatment of Hepatitis C Market was valued at USD 15.67 billion in 2025 and is projected to grow to USD 16.87 billion in 2026, with a CAGR of 8.57%, reaching USD 27.89 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.67 billion
Estimated Year [2026] USD 16.87 billion
Forecast Year [2032] USD 27.89 billion
CAGR (%) 8.57%

Comprehensive orientation to the evolving hepatitis C antiviral landscape that frames clinical, commercial, and operational priorities for decision-makers

Hepatitis C remains a global public health priority and the therapeutic landscape has undergone a rapid transformation over the past decade. Advances in antiviral science have redefined clinical expectations, shifting care from long, side-effect-heavy regimens to shorter, highly effective antiviral courses that target specific viral proteins. These therapeutic advances have fundamentally changed provider behavior, payer assessment frameworks, and patient expectations, and they continue to influence where investment and innovation are concentrated.

This executive summary synthesizes current clinical paradigms, reimbursement dynamics, and commercial strategies relevant to antiviral therapies for hepatitis C. It distills how drug classes and delivery formats intersect with genotype diversity and care settings, and it highlights the operational pressures reshaping R&D and manufacturing. The intent is to provide a strategic vantage point for executives, clinicians, and investors who must align program portfolios and market access plans to a rapidly evolving clinical and regulatory environment.

Throughout this overview, emphasis is placed on actionable interpretation rather than raw numbers, so readers can prioritize investments, anticipate access barriers, and adapt supply chains to maintain resilience and patient continuity of care.

How rapid therapeutic innovation, pricing pressure, and distribution channel evolution are reshaping clinical pathways, commercial models, and manufacturing choices

Therapeutic innovation has driven transformative shifts across the hepatitis C treatment continuum, catalyzing new commercial models and clinical pathways. The emergence of highly potent direct-acting antivirals has altered treatment objectives from viral suppression to sustained virologic response as a practical cure, which in turn has changed referral patterns, testing incentives, and the economics of chronic care management. As a result, stakeholders are refocusing resources on early diagnosis, simplified care algorithms, and pan-genotypic regimens that reduce the need for genotype-specific decision trees.

Simultaneously, scientific advances in mechanism-of-action targeting-spanning protease inhibitors, NS5A inhibitors and nucleoside and non-nucleoside polymerase inhibitors-have generated combination regimens that optimize efficacy while minimizing adverse events. These combination strategies, paired with oral formulations and shorter courses, are enabling expanded treatment in outpatient and homecare settings, prompting a redistribution of revenue and volume across distribution channels. At the same time, competitive pressure from generics and biosimilars has intensified pricing scrutiny, leading manufacturers to explore value-based contracting, bundled care models, and partnerships with payers and public health programs.

Operationally, manufacturers are rethinking manufacturing footprints and forging alliances with contract development and manufacturing organizations to increase flexibility and reduce time to market. Taken together, these shifts create both near-term disruption and long-term opportunities for differentiation through evidence generation, strategic channel engagement, and patient-centered access programs.

Assessment of how 2025 tariff measures are influencing supply chain resilience, procurement behavior, pricing strategies, and patient access dynamics for HCV antivirals

The tariff environment instituted in 2025 has introduced multifaceted implications for supply chains, procurement strategies, and patient access in the hepatitis C antiviral sector. Elevated import costs for active pharmaceutical ingredients and finished dosage forms have prompted manufacturers and distributors to re-evaluate global sourcing strategies, accelerate the qualification of alternate suppliers, and increase reliance on regional contract manufacturing to mitigate cost volatility. These responses have preserved supply continuity in many cases but have also introduced complexity into lead times and quality oversight.

Payer and procurement entities have responded by demanding greater transparency on landed cost and by seeking longer-term purchase agreements that can dampen short-term price shocks. In parallel, some manufacturers have absorbed tariff effects to protect market access for essential therapies, while others have adjusted pricing or delayed launches in specific markets to preserve margins. Clinicians and health systems face indirect consequences as formulary decisions and procurement cycles adapt, potentially affecting regimen availability and formulary positioning for certain formulations or branded products.

Looking ahead, industry players who proactively diversify manufacturing, optimize inventory policies, and engage with policymakers on tariff exemptions for essential medicines will be better positioned to preserve access and manage cost pressures. Coordination with distributors and health systems on demand forecasting and contingency planning remains critical to avoid therapy interruptions for patients living with hepatitis C.

Insight-driven segmentation framework that links product types, mechanisms, therapy models, channels, end users, formulations, and genotypes to strategic commercial and clinical decisions

Segment-specific dynamics determine clinical adoption patterns, commercial positioning, and operational priorities across the hepatitis C antiviral arena. Product type distinctions between direct-acting antivirals, interferons, and ribavirin continue to drive prescribing behavior and therapy optimization, with direct-acting antivirals serving as the backbone of modern regimens while interferons and ribavirin retain niche roles in select clinical circumstances. Mechanism-of-action segmentation delineates clinical value propositions: NS3/4A protease inhibitors deliver rapid viral suppression, NS5A inhibitors provide potent blockade of replication complexes, and NS5B polymerase inhibitors-subdivided into nucleoside and non-nucleoside inhibitors-contribute both high genetic barrier profiles and complementarity in combination therapy design.

Therapy-type considerations, namely combination therapy versus monotherapy, underlie efficacy and resistance management strategies, prompting manufacturers to focus development on synergistic combinations that can shorten treatment duration and enhance cure rates. Distribution channel dynamics across hospital pharmacies, online pharmacies and retail pharmacies affect patient access pathways, with ambulatory and homecare models expanding reach while hospital-centric channels remain critical for complex cases. End-user segmentation-spanning clinics, homecare and hospitals-shapes service delivery models, adherence support mechanisms and reimbursement codes that manufacturers must navigate. Formulation choices between injectable and oral options have profound implications for administration logistics, patient preference and adherence, while genotype diversity across genotypes 1 through 6 continues to influence trial design, labeling strategies and targeted launch sequencing. Together, these segmentation lenses inform portfolio prioritization, pricing strategies and clinical trial enrollment tactics.

Regional imperatives and differentiated access strategies that reconcile heterogeneous regulatory, procurement, and care-delivery landscapes across global markets

Regional dynamics exert a decisive influence over regulatory strategy, access pathways and commercial execution for hepatitis C antivirals. In the Americas, payers and public health programs prioritize large-scale screening initiatives and streamlined access to pan-genotypic regimens, which encourages manufacturers to align launches with national elimination goals and negotiate outcome-based contracts where feasible. Meanwhile, pricing negotiations within private and public sectors push companies to demonstrate real-world value and cost-offsets associated with cure-oriented therapy.

Across Europe, the Middle East & Africa, there is heterogeneity in regulatory timelines, reimbursement frameworks and health system capacity that necessitates tailored market access strategies. High-income European markets typically demand robust comparative-effectiveness evidence and post-launch pharmacovigilance, while many countries in the Middle East and Africa require capacity-building initiatives to support diagnosis and linkage to care. In turn, manufacturers must weigh localized clinical evidence generation and patient support programs against streamlined regulatory submissions when prioritizing resource allocation.

The Asia-Pacific region presents a complex mix of high-burden countries and mature markets, each with distinct procurement and manufacturing opportunities. Several countries in the region emphasize domestic production and tender-based procurement, influencing partnerships and licensing approaches. Collectively, these regional nuances require agile regulatory planning, differentiated pricing and distribution tactics, and investment in local stakeholder engagement to maximize therapeutic uptake and public health impact.

Competitive dynamics and strategic partnerships among innovators, generics, and manufacturing partners that are redefining therapeutic differentiation and market access approaches

Corporate strategies and competitive positioning among leading pharmaceutical and biotech companies are shaping both near-term commercial outcomes and the longer-term evolution of hepatitis C therapeutics. Established innovators continue to defend premium positioning through label expansions, pan-genotypic indications and real-world evidence programs, while simultaneously pursuing lifecycle management via new formulations and simplified dosing schedules. At the same time, entrants and generic manufacturers are intensifying competition in price-sensitive segments, often focusing on high-volume tenders and emerging market access.

Strategic alliances are increasingly common, with originators collaborating with regional partners to expand manufacturing capacity, secure distribution channels, and meet local market requirements. Research-focused organizations invest in next-generation polymerase and NS5A-targeted compounds to address resistance profiles and to create combination opportunities that can differentiate on safety and duration. Moreover, contract manufacturing organizations and specialty distributors are playing a larger role in enabling rapid scale-up and in supporting product launch logistics across diverse channels.

Investors and corporate leaders should monitor patent expiry timelines, litigation outcomes, and regulatory exclusivity windows closely, because these factors will dictate the timing of generic entry and influence pricing dynamics. Firms that combine robust clinical evidence with flexible manufacturing and pragmatic market access initiatives will be best positioned to sustain revenue streams while advancing public health objectives.

Actionable, high-impact corporate and clinical steps for developers and payers to secure sustainable access, mitigate supply risk, and accelerate patient-centered hepatitis C care

Industry leaders should prioritize a sequence of pragmatic actions to convert insight into market advantage. First, invest in pan-genotypic combination regimens and evidence that demonstrates short-course efficacy and improved safety, because such data reduce complexity for clinicians and payers and expand treatable populations. Next, establish flexible manufacturing networks and strategic supplier relationships to mitigate tariff exposure and reduce lead-time risk; regional contract manufacturing and dual-sourcing of key intermediates are particularly effective.

Simultaneously, develop integrated access strategies that align with payer expectations, including value-based contracting, outcome tracking and partnerships with public health programs to support screening and linkage to care. Expand channel strategies to include hospital pharmacies, retail and online pharmacies in coordinated ways that preserve adherence and data capture. Invest in digital adherence tools and patient support services that enable homecare delivery and remote monitoring, thereby reducing the burden on hospital systems and improving long-term outcomes. Finally, pursue targeted geographic launches that match genotype prevalence and health system readiness, and prioritize real-world evidence generation to support reimbursement discussions and to inform label expansions.

Robust mixed-methods research approach combining stakeholder interviews, regulatory and clinical evidence synthesis, and scenario analysis to validate strategic insights

The research underpinning this executive summary employed a mixed-methods approach that balanced primary stakeholder engagement with systematic secondary evidence synthesis. Primary research included structured interviews with clinicians, payers, procurement specialists, and senior executives across pharmaceutical and contract manufacturing organizations, which provided real-world perspectives on prescribing behavior, tender dynamics and supply-chain constraints. Secondary research involved a comprehensive review of peer-reviewed literature, regulatory filings, clinical trial registries, and public health program documentation to triangulate clinical efficacy, safety profiles and policy trends.

Analytical processes included cross-validation of qualitative insights against documented regulatory decisions and publicly available pharmacovigilance data. Scenario analysis was used to evaluate the operational implications of tariff changes and distribution shifts, while segmentation frameworks informed differential strategies across product classes, mechanisms of action, channels and genotypes. Limitations include variability in data transparency across regions and evolving tariff and policy environments; therefore, readers should interpret operational recommendations within the context of ongoing regulatory developments and local procurement practices.

Overall, the methodology emphasizes transparency, reproducibility and direct stakeholder validation to ensure that the recommendations reflect practical constraints and strategic opportunities encountered by market participants.

Strategic synthesis highlighting how clinical progress, access constraints, and operational resilience must be integrated to advance cures and sustain market viability

In summary, the hepatitis C antiviral landscape is characterized by rapid scientific progress, shifting commercial models, and evolving access challenges that together create both urgency and opportunity for manufacturers, payers and health systems. Therapeutic advances have simplified clinical decision-making and expanded the potential for cure, yet pricing pressure, tariff-driven supply risks and heterogeneous regional requirements necessitate agile strategies. Organizations that align clinical development with practical access pathways, diversify manufacturing and distribution arrangements, and invest in real-world evidence generation will achieve the dual objectives of commercial success and public health impact.

The strategic focus should remain on developing regimens that minimize complexity, expanding delivery models that reach underserved populations, and maintaining supply chain flexibility to withstand policy shocks. By integrating clinical differentiation with pragmatic market access planning and operational resilience, stakeholders can accelerate progress toward improved outcomes for people living with hepatitis C while navigating the commercial and regulatory headwinds present in today's global environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Drugs for the Treatment of Hepatitis C Market, by Product Type

  • 8.1. Direct-Acting Antivirals
  • 8.2. Interferons
  • 8.3. Ribavirin

9. Antiviral Drugs for the Treatment of Hepatitis C Market, by Mechanism Of Action

  • 9.1. NS3/4A Protease Inhibitors
  • 9.2. NS5A Inhibitors
  • 9.3. NS5B Polymerase Inhibitors
    • 9.3.1. Non-Nucleoside Inhibitors
    • 9.3.2. Nucleoside Inhibitors

10. Antiviral Drugs for the Treatment of Hepatitis C Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Antiviral Drugs for the Treatment of Hepatitis C Market, by Formulation

  • 11.1. Injectable
  • 11.2. Oral

12. Antiviral Drugs for the Treatment of Hepatitis C Market, by Genotype

  • 12.1. Genotype 1
  • 12.2. Genotype 2
  • 12.3. Genotype 3
  • 12.4. Genotype 4
  • 12.5. Genotype 5
  • 12.6. Genotype 6

13. Antiviral Drugs for the Treatment of Hepatitis C Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Antiviral Drugs for the Treatment of Hepatitis C Market, by End User

  • 14.1. Clinics
  • 14.2. Homecare
  • 14.3. Hospitals

15. Antiviral Drugs for the Treatment of Hepatitis C Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Antiviral Drugs for the Treatment of Hepatitis C Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Antiviral Drugs for the Treatment of Hepatitis C Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Antiviral Drugs for the Treatment of Hepatitis C Market

19. China Antiviral Drugs for the Treatment of Hepatitis C Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. AstraZeneca plc
  • 20.7. Aurobindo Pharma Limited
  • 20.8. Boehringer Ingelheim International GmbH
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. Cipla Limited
  • 20.11. Dr. Reddy's Laboratories Ltd.
  • 20.12. F. Hoffmann-La Roche Ltd
  • 20.13. Gilead Sciences, Inc.
  • 20.14. GlaxoSmithKline plc
  • 20.15. Hetero Drugs Limited
  • 20.16. Johnson & Johnson
  • 20.17. Merck & Co., Inc.
  • 20.18. Natco Pharma Limited
  • 20.19. Novartis AG
  • 20.20. Pfizer Inc.
  • 20.21. Sun Pharmaceutical Industries Ltd.
  • 20.22. Teva Pharmaceutical Industries Ltd.
  • 20.23. Vertex Pharmaceuticals Incorporated
  • 20.24. Viatris Inc.
  • 20.25. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)